Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynepo dosing schedule study in anaemia associated with chronic kidney disease
2006-002052-15Phase 3Terminated
- Sponsor
- Takeda
- Start
- Sep 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin delta in Uraemic Anaemia and chronic kidney disease (CKD) (4 arms), sponsored by Takeda. Primary endpoints: Mean haemoglobin concentration at Week 24 and Mean haemoglobin concentration over Weeks 16 to 24. Started Sep 2006; status: terminated.
02
Drugs
epoetin delta
03
Conditions
Uraemic Anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2006-002052-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002052-15.